Nama's AI scorecard currently rates Kiniksa Pharmaceuticals International Buy (7.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is KNSA's P/E ratio?

Kiniksa Pharmaceuticals International trades at a trailing price-to-earnings ratio of 72.2.

When does KNSA report earnings?

Kiniksa Pharmaceuticals International's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.28.

What is the KNSA price target?

The median analyst price target from 7 analysts is $102.00, with a range of $98.00 – $134.00.

Is KNSA Shariah compliant?

Nama's AAOIFI-style screen reads Kiniksa Pharmaceuticals International as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Kiniksa Pharmaceuticals International (KNSA)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Kiniksa Pharmaceuticals International (KNSA) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $7.37B, a trailing price-to-earnings ratio of 72.2 and a free-cash-flow yield of 1.8%. Over the most recent reported fiscal year, revenue grew 60.1% and free cash flow per share grew 385.5%. Nama's AI scorecard rates it Buy, 7.6 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Buy · 7.6/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Leading · +101.8% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-4.7%

How far the last close sits under the highest price of the past five years.

Market cap	$7.37B
Trailing P/E	72.2
Price / book	10.4
Price / sales	7.8
FCF yield	1.8%
Dividend yield	—
Gross margin	54.3%
Operating margin	13.8%
Net margin	11.6%
Revenue growth (YoY)	+60.1%
Revenue growth (3-yr annual)	+45.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	+385.5%
Beta	0.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

KNSA earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate $0.28). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 27, 2026	$0.56	$0.31	+80.7%	$285.97M
Q2 2026	Jul 28, 2026	$0.30	$0.28	+7.1%	$243.60M
Q1 2026	Apr 28, 2026	$0.27	$0.16	+68.8%	$214.27M
Q4 2025	Feb 24, 2026	$0.17	$0.40	-57.5%	$202.13M

KNSA analyst price target

Median target $102.00 from 7 analysts, ranging $98.00 – $134.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live KNSA data on Nama Insights →

KNSA FAQ

Is KNSA a buy?: Nama's AI scorecard currently rates Kiniksa Pharmaceuticals International Buy (7.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is KNSA's P/E ratio?: Kiniksa Pharmaceuticals International trades at a trailing price-to-earnings ratio of 72.2.
When does KNSA report earnings?: Kiniksa Pharmaceuticals International's next scheduled report is on Feb 23, 2027. Analysts expect EPS of $0.28.
What is the KNSA price target?: The median analyst price target from 7 analysts is $102.00, with a range of $98.00 – $134.00.
Is KNSA Shariah compliant?: Nama's AAOIFI-style screen reads Kiniksa Pharmaceuticals International as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.